Batavia Biosciences releases ‘Amalia,’ a novel manufacturing facility in Leiden, The Netherlands, enhancing their capability in viral vaccine and vector production.
Batavia Biosciences has announced the launch of ‘Amalia,’ a new GMP-ready manufacturing facility in Bilthoven, Netherlands.
This facility marks a significant advancement in the company’s ability to produce viral vaccines and viral vectors for clinical manufacturing. Menzo Havenga, CEO of Batavia Biosciences, highlights that Amalia aligns with the company’s mission to bring medical solutions from the lab to patients, especially in the context of epidemic preparedness.
The facility, equipped with advanced technology and adhering to high-quality standards, is set to play a crucial role in vaccine and viral vector development and production.
Amalia is part of Batavia Biosciences’ broader expansion strategy, with further developments anticipated, including a larger facility in Leiden.
For more details and future updates from Batavia Biosciences, please refer to their official announcements.
Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech...
At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch delegation at the Netherlands...
We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech....